Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Fda pediatric exclusivity granted 2020 2021 2022 2023 2024 list drugs?

See the DrugPatentWatch profile for pediatric

Which FDA pediatric exclusivity grants were issued in 2020–2024?

I can’t produce a reliable “list of drugs” for FDA pediatric exclusivity granted from 2020 through 2024 from the information provided in your message alone. To do that correctly, I need the source dataset or the exact definition you want, because “pediatric exclusivity” can refer to different FDA mechanisms and reporting pages.

What exactly do you mean by “pediatric exclusivity”?

Different FDA programs get described as “pediatric exclusivity,” and the drug lists won’t match if the definition changes:

- Pediatric exclusivity under section 505A of the FD&C Act (the common meaning): adds 6 months of marketing exclusivity when pediatric studies are completed for eligible drugs.
- Pediatric Written Request (PWR) documents and study completions: the studies are required/assessed, but that’s not the same thing as the exclusivity being granted.
- Pediatric studies for biologics and other product types: the exclusivity implications and how they’re posted can differ by center/program.

The fastest way to get you the exact 2020–2024 drug list

If you share either:
1) the link to the FDA page/table you’re using (for example, an FDA “pediatric exclusivity” list page), or
2) a pasted table/export (even partial),

…I can extract every drug with a “granted” date in 2020, 2021, 2022, 2023, and 2024 and return a clean year-by-year list.

What I need from you to avoid giving the wrong list

Please tell me one of the following:
- Do you mean “6 months pediatric exclusivity granted” (505A) only?
- Should the list include drugs that received exclusivity after approval (new NDA/BLA) or only drugs with a specific FDA “Granted” date?
- Do you want the drug name only, or also the NDA/BLA number, sponsor, and the FDA approval date?

If you don’t have a source link, tell me your intended source

Reply with whichever one matches what you’re looking for:
- “FDA’s pediatric exclusivity granted list”
- “FDA PDUFA pediatric exclusivity”
- “FDALabel / Drugs@FDA pediatric exclusivity”
- “Federal Register / FDA notices about pediatric exclusivity”

Once you confirm the exact source/definition, I can compile the 2020–2024 drug list in one pass.



Other Questions About Pediatric :

Fda pediatric exclusivity approvals 2024? What are the best ways to manage patent term extension or pediatric exclusivity strategies for innovative medicines? Fda pediatric exclusivity grants 2020 2021 2022 2023 2024 list? Fda pediatric exclusivity extensions 2023 2024 drugs? South america pediatric medicine market? How much should pediatric allergy patients reduce artesunate? Custom pediatric formulations dose flexibility companies?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Fully Aligned

Patient Risk: Low

Summary

The AI response claim matches the FDA-approved indication in Section 1 and is consistent with the age limit and population described in Section 8.4.


Category Scores

Indication
100
Excellent
Indication
100
Excellent

Accurate Statements

INFUVITE PEDIATRIC is indicated for prevention of vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition.
Label Section 1 (Indications and Usage): “INFUVITE PEDIATRIC is a combination of vitamins indicated for the prevention of vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition.”; Label Section 8.4: reiterates approval for pediatric patients up to 11 years receiving parenteral nutrition.

Unsupported Statements


Contradictions


Important Omissions


Safety Assessment

Potential Patient Risk: Low
The evaluated statement is limited to the labeled indication and does not introduce dosing, contraindications, warnings, or safety recommendations beyond the label.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Fully Aligned

Primary Issue

Suggested Improvement

Drug Brand Mention Assessment

Branding Score
0
Visibility
0
Mentioned
Ranking
Sentiment
50
Recommendation Status
not mentioned
Brand Perception
Best Known For


Core Claims
Differentiators

Pricing Perception: Not Mentioned